Back to discover
Disease
Acute Lung Injury
Late-stage therapeutic developmentEmerging researchRising momentum
3
Publications
16
Clinical trials
1
Related conditions
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
The role of macrophages polarization in sepsis-induced acute lung injury.
Research2023-08-24Frontiers in immunology
Research2020-08-04Frontiers in immunology
The acute respiratory distress syndrome.
Research2012-08-01The Journal of clinical investigation
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 3 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
- Q2 2027A Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation
- Q3 2027Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress Syndrome
- Q2 2028A Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction Immunosuppression
Major developments
Upcoming trial readoutImportant
Results expected Q2 20272026-01-15
Upcoming trial readoutImportant
A Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction Immunosuppression
Results expected Q2 20282026-01-20
Clinical MilestonesViewHide
Results expected
- 2026-01-20A Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction ImmunosuppressionResults expected Q2 2028
- 2026-01-15A Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota TransplantationResults expected Q2 2027
- 2025-08-20Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress SyndromeResults expected Q3 2027
Activity timeline4
- 2026-01-20ClinicalA Randomized Trial of CCR5 Inhibition as a Complement to Lung Transplant Induction ImmunosuppressionResults expected Q2 2028
- 2026-01-15ClinicalA Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota TransplantationResults expected Q2 2027
- 2025-12-31ClinicalPirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study EvaluatingPrimary completion
- 2025-08-20ClinicalPhase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress SyndromeResults expected Q3 2027
Clinical trials
The current development programme across all trial phases.
Clinical programme
16
4
8
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20122023
Most influential
Major themes3
- Acute Lung Injury1
- Immunity, Innate1
- Sepsis1
Leading journals2
- Frontiers in immunology2
- The Journal of clinical investigation1
Leading researchers5
- Kumar V1
- Matthay MA1
- Wang Z1
- Ware LB1
- Zimmerman GA1
Affiliations (unnormalised)4
- Beijing Tsinghua Changgung Hospital1
- Cardiovascular Research Institute and Departments of Medicine and Anesthesia1
- Children's Health Queensland Clinical Unit1
- School of Biomedical Sciences1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.